Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors

Cancer Research

Volumn 64, Issue 19, 2004, Pages 6915-6918

  Ho, Chung Liang ^a   Kurman, Robert J ^a   Dehari, Reiko ^a   Wang, Tian Li ^a   Shih, Ie Ming ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAF GENE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTADENOMA; DISEASE ASSOCIATION; EPITHELIUM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; KRAS GENE; MUTANT; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY SEROUS BORDERLINE TUMOR; OVARY TUMOR; PRECURSOR; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROSA; TUMOR GROWTH;

CYSTADENOMA, SEROUS; FEMALE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 4944250783     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2067     Document Type: Article

References (32)

1. Kinzler KW, Vogelstein B. The genetic basis of human cancer. Toronto: McGraw-Hill, 1998.
2. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science (Wash D C) 1998;280:1036-7.
3. Kern SE. Advances from genetic clues in pancreatic cancer. Curr Opin Oncol 1998;10:74-80.
4. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4.
5. Shih I-M, Kurman RJ. Ovarian tumorigenesis- a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
6. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (Bethesda) 2003;95:484-6.
7. Singer G, Kurman RJ, Chang H-W, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
8. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996;20:1319-30.
9. Cheng EJ, Kurman RJ, Wang M, et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Investig 2004;84:778-84.
10. Yang DH, Smith ER, Cohen C, et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer (Phila) 2002;94:2380-92.
11. Sieben NLG, Macropoulos P, Roemen G, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumors. J Pathol 2004;202: 336-40.
12. Cuatrecasas M, Erill N, Musulen E, et al. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer (Phila) 1998;82:1088-95.
13. Zheng J, Benedict WF, Xu HJ, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas [see comments]. J Natl Cancer Inst (Bethesda) 1995;87:1146-53.
14. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
15. Leitao MM, Soslow RA, Baergen RN, et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004;93:301-6.
16. Kappes S, Milde-Langosch K, Kressin P, et al. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 1995;64:52-9.
17. Singer G, Stohr R, Dehari R, et al. Patterns of p53 mutations separate ovarian serous borderline tumors, low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol. In press 2004.
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature (Lond) 2002;417:949-54.
19. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
20. Chan TL, Zhao W, Leung SY, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003;63:4878-81.
21. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer (Phila) 2002;95:2380-9.
22. Conway C, Zalud I, Dilena M et al. Simple cyst in the postmenopausal patient: detection and management. J Ultrasound Med 1998;17:369-72; quiz 373-4.
23. Oyelese Y, Kueck AS, Barter JF, et al. Asymptomatic postmenopausal simple ovarian cyst. Obstet Gynecol Surv 2002;57:803-9.
24. Christensen JT, Boldsen JL, Westergaard JG. Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception 2002;66:153-7.
25. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, editor, Blaustein's pathology of the female genital tract, edition 5. New York: Springer Verlag, 2002. p. 791-904.
26. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers [news; comment]. Nature (Lond) 1997;386:761, 763.
27. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
28. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65.
29. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003;30(5 Suppl 16): 105-16.
30. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
31. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999;96:9236-41.
32. Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003;100:8817-22.